Switch theme
Sign up to access all valuation multiples
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
1999
n/a
LTM Revenue $3.8B
LTM EBITDA $375M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DaShenLin Pharmaceutical has a last 12-month revenue of $3.8B and a last 12-month EBITDA of $375M.
In the most recent fiscal year, DaShenLin Pharmaceutical achieved revenue of $3.4B and an EBITDA of $433M.
DaShenLin Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DaShenLin Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.4B | $3.7B | XXX | XXX | XXX |
| Gross Profit | $881M | $1.1B | XXX | XXX | XXX |
| Gross Margin | 26% | 30% | XXX | XXX | XXX |
| EBITDA | $433M | $357M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 10% | XXX | XXX | XXX |
| Net Profit | $109M | $143M | XXX | XXX | XXX |
| Net Margin | 3% | 4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, DaShenLin Pharmaceutical's stock price is CNY 17 (or $2).
DaShenLin Pharmaceutical has current market cap of CNY 19.7B (or $2.7B), and EV of CNY 21.3B (or $2.9B).
See DaShenLin Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $2.7B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, DaShenLin Pharmaceutical has market cap of $2.7B and EV of $2.9B.
DaShenLin Pharmaceutical's trades at 0.8x LTM EV/Revenue multiple, and 7.8x LTM EBITDA.
Analysts estimate DaShenLin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for DaShenLin Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.9B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.2x | XXX | XXX | XXX |
| P/E | 18.4x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | 22.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDaShenLin Pharmaceutical's NTM/LTM revenue growth is 14%
DaShenLin Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, DaShenLin Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate DaShenLin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for DaShenLin Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 24% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 28% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DaShenLin Pharmaceutical acquired XXX companies to date.
Last acquisition by DaShenLin Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . DaShenLin Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was DaShenLin Pharmaceutical founded? | DaShenLin Pharmaceutical was founded in 1999. |
| Where is DaShenLin Pharmaceutical headquartered? | DaShenLin Pharmaceutical is headquartered in China. |
| Is DaShenLin Pharmaceutical publicy listed? | Yes, DaShenLin Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical trades under 603233 ticker. |
| When did DaShenLin Pharmaceutical go public? | DaShenLin Pharmaceutical went public in 2017. |
| Who are competitors of DaShenLin Pharmaceutical? | Similar companies to DaShenLin Pharmaceutical include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's current market cap is $2.7B |
| What is the current revenue of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12-month revenue is $3.8B. |
| What is the current EBITDA of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12-month EBITDA is $375M. |
| What is the current EV/Revenue multiple of DaShenLin Pharmaceutical? | Current revenue multiple of DaShenLin Pharmaceutical is 0.8x. |
| What is the current EV/EBITDA multiple of DaShenLin Pharmaceutical? | Current EBITDA multiple of DaShenLin Pharmaceutical is 7.8x. |
| What is the current revenue growth of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical revenue growth between 2023 and 2024 was 9%. |
| Is DaShenLin Pharmaceutical profitable? | Yes, DaShenLin Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
